MedTech Catapult opens in Biopolis

It supports MedTech innovators in bringing products to market and connecting with local manufacturers.

MedTech Catapult, a national initiative led by A*STAR, has launched at Biopolis.

This $38m initiative, first announced during the Committee of Supply debate in March 2024, aims to accelerate the development and commercialisation of high-value life science instruments and medical devices.

“Through purposeful productisation, our national platforms such as MedTech Catapult guide MedTech innovations from ideation to regulatory approval and scalable manufacturing, ensuring they are market-ready,” said Irene Cheong, assistant chief executive (Innovation & Enterprise) at A*STAR.

In its first year, MedTech Catapult has supported projects such as Castomize’s Remouldable Orthopaedic Cast (4D-printed remouldable short arm cast for wrist fractures) and Dornier MedTech’s Smart System for Enhanced Laser Lithotripsy (kidney stone treatment).

In addition, MedTech Catapult unveiled a local supplier and contract manufacturer directory titled “Medtech Manufacturing in Singapore: A Commitment to Engineering Excellence.”

This directory, jointly supported by the Ministry of Trade and Industry, A*STAR, Enterprise Singapore (EnterpriseSG), the Singapore Economic Development Board, and the Singapore Precision Engineering and Technology Association, highlights the differentiated capabilities of local manufacturers.

It provides an overview of local capabilities, aiding medtech product owners to find potential local partners for co-innovation opportunities and scaling production efficiently. Additionally, it will be regularly updated to connect medtech innovators to the right manufacturing partners.